Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus FOLFIRI as second-line therapy for unresectable neuroendocrine neoplasms
ChiCTR2200067231Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pumitamig, irinotecan, fluorouracil and folinic acid in apudoma (NET), sponsored by Chinese PLA General Hospital. Primary endpoints: Objective response rate and Incidence and severity of treatment-related adverse events. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
pumitamigirinotecanfluorouracilfolinic acid
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2200067231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067231.